IONS - Ionis Pharmaceuticals Inc Stock Price, Fair Value and News

$81.75+0.44 (+0.54%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IONS Price Action

Last 7 days

-1.1%

Last 30 days

11%

Last 90 days

37.7%

Trailing 12 Months

128.3%

IONS RSI Chart

IONS Valuation

Market Cap

13.4B

Price/Earnings (Trailing)

-52.27

Price/Sales (Trailing)

13.86

EV/EBITDA

-56.03

Price/Free Cashflow

-44.27

IONS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IONS Fundamentals

IONS Revenue

Revenue (TTM)

967.0M

Rev. Growth (Yr)

17.12%

Rev. Growth (Qtr)

-65.33%

IONS Earnings

Earnings (TTM)

-256.3M

Earnings Growth (Yr)

8.45%

Earnings Growth (Qtr)

-204.09%

IONS Profitability

EBT Margin

-26.76%

Return on Equity

-41.48%

Return on Assets

-8.45%

Free Cashflow Yield

-2.26%

IONS Investor Care

Shares Dilution (1Y)

2.58%

Diluted EPS (TTM)

-1.69

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	717.3M	944.1M	967.0M	0
2024	776.6M	813.5M	803.1M	705.1M
2023	576.0M	630.6M	615.0M	787.6M
2022	840.8M	848.8M	875.5M	587.4M
2021	707.5M	687.7M	660.7M	810.5M
2020	958.8M	940.5M	932.7M	729.3M
2019	752.5M	798.5M	821.0M	1.1B
2018	547.3M	552.8M	579.9M	599.7M
2017	425.5M	499.3M	506.7M	518.7M
2016	258.0M	176.0M	237.8M	346.6M
2015	248.6M	257.4M	274.9M	283.7M
2014	132.1M	151.1M	171.5M	214.2M
2013	122.2M	112.9M	124.9M	147.3M
2012	101.2M	123.7M	114.6M	102.0M
2011	99.7M	101.0M	93.1M	99.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

CEO	Dr. Brett P. Monia Ph.D.
WEBSITE	ionispharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	796

Ionis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ionis Pharmaceuticals Inc? What does IONS stand for in stocks?

IONS is the stock ticker symbol of Ionis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ionis Pharmaceuticals Inc (IONS)?

As of Wed Dec 03 2025, market cap of Ionis Pharmaceuticals Inc is 13.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers.

Is Ionis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IONS is over valued or under valued. Whether Ionis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ionis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IONS.

What is Ionis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, IONS's PE ratio (Price to Earnings) is -52.27 and Price to Sales (PS) ratio is 13.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IONS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ionis Pharmaceuticals Inc's stock?

In the past 10 years, Ionis Pharmaceuticals Inc has provided 0.032 (multiply by 100 for percentage) rate of return.